Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.97 USD | +0.47% | +4.13% | +10.19% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 34.16 and 25.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.75 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.19% | 11.77B | C+ | ||
+8.07% | 219B | B | ||
+6.59% | 183B | B- | ||
+11.26% | 133B | B- | ||
+26.57% | 108B | A- | ||
+0.65% | 63.06B | A- | ||
+13.35% | 52.02B | B+ | ||
-0.62% | 48.2B | B+ | ||
-0.93% | 40.37B | A | ||
+11.54% | 39.35B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BRKR Stock
- Ratings Bruker Corporation